DALLAS, Nov. 17, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Poniard Pharmaceuticals Inc. (Nasdaq:PARD). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Poniard Pharmaceuticals Inc. (Nasdaq:PARD) should be of particular interest to other pharmaceutical companies: Bristol-Myers Squibb Co. (NYSE:BMY), Immunogen Inc. (Nasdaq:IMGN) and Sanofi-Aventis. (NYSE:SNY).
It is available at: http://www.beaconequity.com/i/PARD
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Poniard Pharmaceuticals Inc. (PARD) is a biopharmaceutical company focused on the development and commercialization of cancer therapy products. Its lead product candidate is picoplatin, a platinum-based cancer therapy. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance in the treatment of solid tumors. The Company initiated a phase III SPEAR (Study of Picoplatin Efficacy after Relapse) trial of picoplatin in small cell lung cancer.
In the report, the analyst notes:
"The Company reported a net loss of $9.9 million ($0.29 diluted loss per share on a loss applicable to common shares of $10.0 million) for the quarter ended September 30, 2009, compared with a net loss of $12.2 million ($0.36 diluted loss per share on a loss applicable to common shares of $12.4 million) for the quarter ended September 30, 2008.
"PARD today announced that its pivotal phase III SPEAR (Study of Picoplatin Efficacy after Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC) did not meet its primary endpoint of overall survival. The analysis, based on 320 evaluable events (patient deaths), showed a hazard ratio of 0.82 with a p value of 0.089."
To read the entire report visit: http://www.beaconequity.com/i/PARD
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.